Healthcare Veteran John Fletcher Joins MRI Interventions’ Board of Directors
May 11 2017 - 8:30AM
MRI Interventions, Inc. (OTCQB:MRIC) is pleased to announce that
John Fletcher has been appointed to MRI Interventions’ Board of
Directors. Mr. Fletcher, founder and managing partner of Fletcher
Spaght, Inc., brings more than 30 years of experience in healthcare
with an emphasis in the field of medical devices. He succeeds
Andrew K. Rooke, who stepped down from MRI Interventions’ Board
after nearly six years of exceptional service to the company.
In addition to serving as managing partner of
Fletcher Spaght, Mr. Fletcher is Chairman of the Board of
Spectranetics, Inc. (Nasdaq:SPNC), a medical device company focused
on minimally invasive procedures in the cardiovascular system.
During his 15-year tenure on the Board, Spectranetics has seen
continued expansion of its therapeutic platforms and significant
growth in its commercial business. Mr. Fletcher is also a member of
the Board of Directors of Axcelis Technologies, Inc (Nasdaq:ACLS),
and Metabolon, Inc., a health technology company.
“We are thrilled to have John join the Board of
Directors,” said Frank Grillo, President and CEO of MRI
Interventions, Inc. “John’s extensive experience in the medical
device industry, as well as his leadership on a number of boards,
both public and private, will be a great addition to our
company.”
“I am pleased to join the Board of Directors of MRI
Interventions,” said John Fletcher. “As the industry leader
in the growing field of real-time, MRI-guided procedures, MRI
Interventions is well positioned to advance patient care in the
field of neurosurgery and beyond. I am looking forward to
working with the team.”
Prior to founding Fletcher Spaght, Inc., John was a
Senior Manager at The Boston Consulting Group. Mr. Fletcher was a
PhD candidate in International Business at The Wharton School,
University of Pennsylvania, during which time he also earned a
Master’s Degree in International Finance from Central Michigan
University. He received his Masters of Business Administration from
Southern Illinois University and prior to that a Bachelor of
Business Administration from George Washington University.
Mr. Rooke’s tenure as a member of MRI
Interventions’ Board of Directors dates back to 2011, the
third-longest period of service among currently active Board
members.
“Andy Rooke has been a Board member for nearly 6
years, he is a significant shareholder of the company, and an
invaluable advisor to all of the executive team,” said Frank
Grillo, President and CEO of MRI Interventions, Inc. “Andy
has been a great supporter of our company, and after six years of
support and insight, we will miss Andy, although his advice will
carry us forward for years to come.”
About MRI Interventions,
Inc.
Building on the imaging power of magnetic resonance
imaging (“MRI”), MRI Interventions is creating innovative platforms
for performing the next generation of minimally invasive surgical
procedures in the brain. The ClearPoint Neuro Navigation
System, which has received 510(k) clearance and is CE marked,
utilizes a hospital’s existing diagnostic or intraoperative MRI
suite to enable a range of minimally invasive procedures in the
brain. For more information, please visit
www.mriinterventions.com.
Forward-Looking Statements
Statements herein concerning the Company’s plans,
growth and strategies may include forward-looking statements within
the context of the federal securities laws. Statements regarding
the Company's future events, developments and future performance,
as well as management's expectations, beliefs, plans, estimates or
projections relating to the future, are forward-looking statements
within the meaning of these laws. Uncertainties and risks may cause
the Company's actual results to differ materially from those
expressed in or implied by forward-looking statements. Particular
uncertainties and risks include those relating to: the Company’s
ability to obtain additional financing; estimates regarding the
sufficiency of the Company’s cash resources; future revenues from
sales of the Company’s ClearPoint Neuro Navigation System products;
and the Company’s ability to market, commercialize and achieve
broader market acceptance for the Company’s ClearPoint Neuro
Navigation System products. More detailed information on
these and additional factors that could affect the Company’s actual
results are described in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K for the year ended December
31, 2016, which has been filed with the Securities and Exchange
Commission, as well as the Company’s Quarterly Report on Form 10-Q
for the quarter ended March 31, 2017, which has been filed with the
Securities and Exchange Commission.
Contact:
Harold A. Hurwitz, Chief Financial Officer
(949) 900-6833
Matt Kreps, Darrow Associates Investor Relations
(512) 696-6401; mkreps@darrowir.com
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
The Spectranetics Corp. (MM) (NASDAQ:SPNC)
Historical Stock Chart
From Apr 2023 to Apr 2024